ASLAN PHARMACEUTICALS ADR REP 5 (NASDAQ:ASLN) Stock Rating Lowered by Zacks Investment Research

ASLAN PHARMACEUTICALS ADR REP 5 (NASDAQ:ASLN) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Thursday, September 20th.

According to Zacks, “ASLAN Pharmaceuticals Limited operates as a clinical-stage biotechnology company. It develops drugs, medicines and novel therapeutics for the treatment of patients with oncology, respiratory and inflammatory diseases. The company’s product portfolio includes Varlitinib, ASLAN004, ASLAN002 and ASLAN003 both are in clinical stage. ASLAN Pharmaceuticals Limited is based in Singapore. “

Other analysts have also recently issued research reports about the company. BTIG Research began coverage on ASLAN PHARMACEUTICALS ADR REP 5 in a research report on Wednesday, May 30th. They issued a “buy” rating and a $16.00 price objective for the company. Leerink Swann began coverage on ASLAN PHARMACEUTICALS ADR REP 5 in a research report on Wednesday, May 30th. They issued a “market perform” rating and a $7.00 price objective for the company. HC Wainwright began coverage on ASLAN PHARMACEUTICALS ADR REP 5 in a research report on Wednesday, May 30th. They issued a “buy” rating and a $12.00 price objective for the company. Finally, Piper Jaffray Companies began coverage on ASLAN PHARMACEUTICALS ADR REP 5 in a research note on Wednesday, May 30th. They issued an “overweight” rating for the company. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $10.94.

NASDAQ:ASLN traded down $0.07 during midday trading on Thursday, hitting $7.30. The stock had a trading volume of 6,402 shares, compared to its average volume of 42,421. ASLAN PHARMACEUTICALS ADR REP 5 has a one year low of $5.08 and a one year high of $10.44.

ASLAN PHARMACEUTICALS ADR REP 5 (NASDAQ:ASLN) last announced its earnings results on Monday, August 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.06). As a group, equities research analysts predict that ASLAN PHARMACEUTICALS ADR REP 5 will post -1.34 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. MYDA Advisors LLC purchased a new position in shares of ASLAN PHARMACEUTICALS ADR REP 5 during the 2nd quarter valued at about $195,000. Platinum Investment Management Ltd. acquired a new stake in shares of ASLAN PHARMACEUTICALS ADR REP 5 during the 2nd quarter valued at about $2,532,000. Finally, Temasek Holdings Private Ltd acquired a new stake in shares of ASLAN PHARMACEUTICALS ADR REP 5 during the 2nd quarter valued at about $12,660,000. Institutional investors and hedge funds own 10.93% of the company’s stock.

ASLAN PHARMACEUTICALS ADR REP 5 Company Profile

ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, develops therapeutics for the treatment cancer in Asia, the United States, Europe, and internationally. The company's product pipeline includes Varlitinib, a novel agent, which has completed Phase II studies in gastric and breast cancer, and entered into pivotal studies for biliary tract cancer; ASLAN002, a potent cMET and Recepteur d'Origine Nantais (RON) inhibitor that is in Phase II development for the treatment of gastric and breast cancer; and ASLAN003, a novel DHODH inhibitor, which is in Phase I clinical trials to treat acute myeloid leukemia and solid tumors.

Featured Article: Yield Curve

Get a free copy of the Zacks research report on ASLAN PHARMACEUTICALS ADR REP 5 (ASLN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ASLAN PHARMACEUTICALS ADR REP 5 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN PHARMACEUTICALS ADR REP 5 and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply